Riding the wave of NFT popularity, game development company iCandy Interactive (ASX: ICI) has confirmed their first NFT-based game, League of Super Misfits, will be launched within two months while also boldly declaring the game will generate at least $4 million in revenue. League of Super Misfits, aka The Misfits, is a collaborative title between
Read More
Starbucks never really took off in Australia. We just couldn’t get behind the sickly sweet, whipped cream covered combos that our American friends love so much. Starbucks quickly realised that our local coffee was way too good to even compete with, ultimately leading to the chain closing 61 stores in 2008 with a $143 million
Read More
With concentrated initiatives to convert years of R&D into profitability, water tech company De.mem (ASX: DEM) finally has that in site, an inflection into the green that will be accelerated by their expansion in Victoria through the neat acquisition. Although the majority of De.mem’s water treatment products have been developed for commercial applications, such as
Read More
As is becoming the case across the consumer products industry, millenials are wielding unprecedented power through irrational spending and influencer marketing. So it comes as no surprise that infant formula manufacturer Bubs (ASX: BUB) has launched a new natural A2 beta-casein protein product to quench their demand. The new product is an extension of Bubs’
Read More
Noxopharm (ASX: NOX) will hopefully see an increase in value of their flagship drug following this morning’s announcement. The Company has been granted Orphan Drug Designation from the United States FDA for their proprietary drug, Veyonda, for the treatment of soft tissue sarcoma. Orphan Drug Designation is given to certain drugs and biologics that show promise
Read More
Babies born before 37 weeks of pregnancy are considered premature, and often are at risk of getting sick or suffering developmental issues. Multiple studies have confirmed that there is an interplay between prematurity and childrens’ intelligence quotient (IQ). Premature babies often have lower IQs than their full term peers. To help premature babies reach their
Read More
“What’s your best price on this?” “Mate, it’s the price it’s listed at. If I wanted less, I would have listed it less.” It’s a conversion we’ve all had on Facebook marketplace as unscrupulous bargain hunters think their cash is more valuable than others, while unashamedly asking for further discounts. Oddly enough, such conversations perforate
Read More
Continuing to build on the momentum established over the past two years since prioritising the US school market as a priority, education tech company Family Zone (ASX: FZO) now has more than 1 million students signed up to trials of the tech. With an education system that groups schools within districts, the US market has
Read More
Australians are a smart bunch. Although the pavlova is disputed, we gladly claim awesome inventions like the black box flight recorder, spray-on skin, the cochlear implant, plastic money and fairy bread (arguably the greatest invention of them all). Whilst I’m not sure much could compete with fairy bread, 4DMedical (ASX: 4DX) are giving it a
Read More
Clinical stage pharmaceutical company Pharmaxis (PXS: ASX) is full steam ahead with their Phase 2 clinical trial for flagship drug, PXS-5505. The Company has launched new clinical trial sites in Taiwan in a planned expansion to boost patient recruitment. Designed for use in the treatment of myelofibrosis, a rare blood cancer with a poor prognosis,
Read More
